Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.
- EligibilityCriteria: Inclusion Criteria:  Survivors of cancer Age 18 or older Speak and understand English Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) ≤10 years prior to enrollment. Have a baseline level of fatigue, as determined by reporting a score of 4 or higher for the question, "In the last week, how bad was your worst fatigue on a scale from 0-10?" Be willing to commit to the fucoidan supplement dosing and delivery method, to complete evaluation instruments, and to attend all study visits. Completed Informed Consent  Exclusion Criteria:  Current warfarin or other anti-coagulation medication use. Current use of supplements that contain fucoidan Any allergy to fucoidan Be diagnosed with a major psychiatric illness requiring hospitalization within the last year. Be diagnosed with dementia. Be pregnant or nursing - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult